About CUGBP Elav-like family member 6
CUGBP Elav-like family member 6 (CELF6) is a protein
from Homo sapiens identified by UniProt accession
Q96J87, 481 residues long.
MolForge cross-references it against 0 known binders and
19 disease associations.
Target properties
| Protein name | CUGBP Elav-like family member 6 |
| UniProt accession | Q96J87 |
| Gene | CELF6 |
| Organism | Homo sapiens |
| Length | 481 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (19)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.26
- aspartate aminotransferase measurement · score 0.25
- brain measurement · score 0.05
- Paraganglioma · score 0.03
- neoplasm · score 0.03
- body height · score 0.03
- triglyceride measurement · score 0.02
- cancer · score 0.02
- sitting height measurement · score 0.02
- triple-negative breast cancer · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96J87-F1 | alphafold | PREDICTED | 67.71 | — |
Amino-acid sequence (481 residues)
MAAAPGGSAQ PAGPGPRLGF STADSGVGMS GLNPGPAVPM KDHDAIKLFV GQIPRGLDEQ DLKPLFEEFG RIYELTVLKD RLTGLHKGCA FLTYCARDSA LKAQSALHEQ KTLPGMNRPI QVKPAASEGR GEDRKLFVGM LGKQQGEEDV RRLFQPFGHI EECTVLRSPD GTSKGCAFVK FGSQGEAQAA IRGLHGSRTM AGASSSLVVK LADTDRERAL RRMQQMAGHL GAFHPAPLPL GACGAYTTAI LQHQAALLAA AQGPGLGPVA AVAAQMQHVA AFSLVAAPLL PAAAANSPPG SGPGTLPGLP APIGVNGFGP LTPQTNGQPG SDTLYNNGLS PYPAQSPGVA DPLQQAYAGM HHYAAAYPSA YAPVSTAFPQ QPSALPQQQR EGPEGCNLFI YHLPQEFGDA ELIQTFLPFG AVVSAKVFVD RATNQSKCFG FVSFDNPTSA QTAIQAMNGF QIGMKRLKVQ LKRPKDANRP Y
Explore CUGBP Elav-like family member 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets